AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
33.83
+0.10 (+0.30%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close33.73
Open34.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range33.69 - 34.04
52 Week Range25.55 - 35.60
Volume1,277,344
Avg. Volume4,004,412
Market Cap82.801B
Beta0.65
PE Ratio (TTM)22.19
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.90 (2.69%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey9 hours ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]

  • Parkinson's Space in Focus as Acorda Stops Tozadenant Trial
    Zacksyesterday

    Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

    Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.

  • The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca

    The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca

  • Top Research Reports on Walmart, NVIDIA and Procter & Gamble
    Zacks3 days ago

    Top Research Reports on Walmart, NVIDIA and Procter & Gamble

    Top Research Reports on Walmart, NVIDIA and Procter & Gamble

  • Forbes3 days ago

    For Parkinson's Patients Like Jesse Jackson, Artificial Intelligence Shows Real Promise

    US civil rights activist Jesse Jackson disclosed that he has been diagnosed with Parkinson’s disease. Unfortunately for Jackson, and more than 10 million worldwide living with Parkinson's, there's no cure. However, a new partnership between AstraZeneca and Berg believes AI will be able to prevent it

  • Reuters3 days ago

    Roche win boosts case for adding chemo to cancer immunotherapy

    Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.

  • Reuters3 days ago

    Roche win boosts case for adding chemo to cancer immunotherapy

    Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.

  • Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss
    Zacks3 days ago

    Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss

    Political uncertainty in the United Kingdom and commodity prices weighed on Europe's stocks over last week.

  • Market Realist3 days ago

    AstraZeneca’s Other Products in 3Q17

    The Other Products segment reported revenues of $991 million during 3Q17, a 17% fall in constant exchange rates compared to 3Q16.

  • Market Realist3 days ago

    Performance of AstraZeneca’s Oncology Segment in 3Q17

    AstraZeneca’s (AZN) Oncology segment reported revenues of ~$1 billion during 3Q17, a 19% growth at constant exchange rates.

  • Capital Cube6 days ago

    ETFs with exposure to AstraZeneca Plc : November 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Market Realist6 days ago

    AstraZeneca’s Respiratory Segment in 3Q17

    AstraZeneca’s (AZN) Respiratory segment is one of its key growth platforms. For 3Q17, the segment's revenues fell 2% at constant exchange rates to ~$1.1 billion.

  • InvestorPlace6 days ago

    Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

    Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks6 days ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • Market Realist6 days ago

    AstraZeneca’s Cardiovascular and Metabolic Diseases Segment

    Brilinta reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17.

  • Market Realist6 days ago

    How AstraZeneca’s Growth Platforms Performed in 3Q17

    The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17.

  • Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids
    Bloomberg7 days ago

    Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids

    AstraZeneca Plc is in talks to settle a Texas lawsuit claiming that the company fleeced the state’s Medicaid program by fraudulently marketing one of its top drugs, according to court filings.

  • Market Realist7 days ago

    AstraZeneca’s Performance by Segment in 3Q17

    The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.

  • Market Realist7 days ago

    Why AstraZeneca’s Revenues Rose in 3Q17

    AstraZeneca's (AZN) overall revenue growth was 9%, driven by a substantial growth in externalization revenues to $1.~4 billion, partially offset by a 2% fall in product sales.

  • Market Realist7 days ago

    AstraZeneca’s Valuation after 3Q17 Earnings

    In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

  • Reuters7 days ago

    AstraZeneca ticks another box as U.S. approves severe asthma drug

    AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares in AstraZeneca were 1 percent higher on Wednesday following the overnight news.

  • AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
    Zacks7 days ago

    AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

    AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

  • AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
    Capital Cube7 days ago

    AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AstraZeneca Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of AstraZeneca Plc – Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc Sponsored ADR, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Biogen Inc. and Celgene ... Read more (Read more...)

  • Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
    Zacks7 days ago

    Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

    Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

  • AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
    Zacks8 days ago

    AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

    AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.